These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 24528690

  • 1. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH.
    J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
    [Abstract] [Full Text] [Related]

  • 2. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH.
    Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [Abstract] [Full Text] [Related]

  • 3. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH.
    Lipids Health Dis; 2015 Sep 02; 14():98. PubMed ID: 26328624
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul 02; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 5. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
    Morton AM, Furtado JD, Lee J, Amerine W, Davidson MH, Sacks FM.
    J Clin Lipidol; 2016 Jul 02; 10(6):1442-1451.e4. PubMed ID: 27919362
    [Abstract] [Full Text] [Related]

  • 6. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia.
    Blair HA, Dhillon S.
    Am J Cardiovasc Drugs; 2014 Oct 02; 14(5):393-400. PubMed ID: 25234378
    [Abstract] [Full Text] [Related]

  • 7. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

  • 8. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
    Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA.
    J Cardiovasc Pharmacol; 2009 Sep 15; 54(3):196-203. PubMed ID: 19597368
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
    Mozaffarian D, Maki KC, Bays HE, Aguilera F, Gould G, Hegele RA, Moriarty PM, Robinson JG, Shi P, Tur JF, Lapointe JF, Aziz S, Lemieux P, TRILOGY (Study of CaPre in Lowering Very High Triglycerides) investigators.
    JAMA Netw Open; 2022 Jan 04; 5(1):e2141898. PubMed ID: 34989797
    [Abstract] [Full Text] [Related]

  • 10. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
    Bays HE, Hallén J, Vige R, Fraser D, Zhou R, Hustvedt SO, Orloff DG, Kastelein JJ.
    J Clin Lipidol; 2016 Jan 04; 10(1):181-91.e1-2. PubMed ID: 26892135
    [Abstract] [Full Text] [Related]

  • 11. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
    Maki KC, Bays HE, Ballantyne CM, Underberg JA, Kastelein JJP, Johnson JB, Ferguson JJ.
    J Am Heart Assoc; 2022 Mar 15; 11(6):e024176. PubMed ID: 35232215
    [Abstract] [Full Text] [Related]

  • 12. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.
    Stroes ESG, Susekov AV, de Bruin TWA, Kvarnström M, Yang H, Davidson MH.
    J Clin Lipidol; 2018 Mar 15; 12(2):321-330. PubMed ID: 29289538
    [Abstract] [Full Text] [Related]

  • 13. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
    Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E.
    Curr Med Res Opin; 2010 Apr 15; 26(4):907-15. PubMed ID: 20156032
    [Abstract] [Full Text] [Related]

  • 14. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 Apr 15; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 15. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
    Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, Davidson M.
    Vasc Health Risk Manag; 2013 Apr 15; 9():563-73. PubMed ID: 24124374
    [Abstract] [Full Text] [Related]

  • 16. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
    Bays HE, Maki KC, Doyle RT, Stein E.
    Postgrad Med; 2009 Sep 15; 121(5):145-50. PubMed ID: 19820283
    [Abstract] [Full Text] [Related]

  • 17. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels.
    Berge K, Musa-Veloso K, Harwood M, Hoem N, Burri L.
    Nutr Res; 2014 Feb 15; 34(2):126-33. PubMed ID: 24461313
    [Abstract] [Full Text] [Related]

  • 18. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
    Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM.
    J Clin Lipidol; 2009 Oct 15; 3(5):332-40. PubMed ID: 21291831
    [Abstract] [Full Text] [Related]

  • 19. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
    Dunbar RL, Gaudet D, Davidson M, Rensfeldt M, Yang H, Nilsson C, Kvarnström M, Oscarsson J.
    Lipids Health Dis; 2020 May 30; 19(1):117. PubMed ID: 32473640
    [Abstract] [Full Text] [Related]

  • 20. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
    Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF.
    J Clin Lipidol; 2012 May 30; 6(6):573-84. PubMed ID: 23312053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.